Scarica l'app Stockscreener
68.43
4.72%
-3.39
Dopo l'orario di chiusura:
67.95
-0.48
-0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$71.82
Aprire:
$70
Volume 24 ore:
2.57M
Relative Volume:
0.91
Capitalizzazione di mercato:
$6.22B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-24.44
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-8.66%
1M Prestazione:
+11.83%
6M Prestazione:
+81.13%
1 anno Prestazione:
+39.65%
Intervallo 1D:
$67.82
$71.52
Intervallo di 1 settimana:
$64.80
$78.00
Portata 52W:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
68.43 | 6.31B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 1,076 Shares of Stock - MarketBeat
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 4,242 Shares of Stock - MarketBeat
Visualizing CRISPR Therapeutics AG stock with heatmaps2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Tick level data insight on CRISPR Therapeutics AG volatilityTrade Volume Summary & Fast Entry and Exit Trade Plans - newser.com
CRISPR Therapeutics (CRSP) Plans to Sell $600 Million in Shares - GuruFocus
CRISPR Therapeutics files for $600M stock offering (CRSP:NASDAQ) - Seeking Alpha
Interchange Capital Partners LLC Has $38,000 Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics files to offer up to $600 million in new common shares By Investing.com - Investing.com Australia
22,967 Shares in CRISPR Therapeutics AG $CRSP Bought by Concurrent Investment Advisors LLC - MarketBeat
Kulkarni, CRISPR therapeutics CEO, sells $282k in shares By Investing.com - Investing.com South Africa
Crispr Therapeutics (CRSP) general counsel sells $71k in shares - Investing.com
Crispr Therapeutics AG Files $600M Share Offering - TipRanks
Crispr Therapeutics files to offer up to $600 million in new common shares - Investing.com
CRISPR Therapeutics AG Announces $600 Million Share Offering - TradingView
Key resistance and support levels for CRISPR Therapeutics AG2025 Sector Review & Safe Entry Point Alerts - newser.com
Analyzing net buyer seller activity in CRISPR Therapeutics AGPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
3 Monster Stocks to Hold for the Next 10 Years - AOL.com
SyNTase Gene Editor Corrects Antitrypsin Deficiency In Vivo - CRISPR Medicine News
Blair William & Co. IL Reduces Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Receives a Buy from Citizens JMP - The Globe and Mail
Is CRISPR Therapeutics AG stock cheap compared to fundamentalsIPO Watch & Fast Moving Market Watchlists - newser.com
Will CRISPR Therapeutics AG continue its uptrendMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
Crispr Therapeutics: This Cheap Stock to Buy Is Up 65% in 2025 - Morningstar Canada
Crispr: Investors Waiting Patiently For In-Vivo - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 6.1%Here's Why - MarketBeat
Visual analytics tools that track CRISPR Therapeutics AG performanceMarket Sentiment Summary & Daily Price Action Insights - newser.com
Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo - TipRanks
Crispr Therapeutics AG: Promising Advancements in Gene Editing and Strategic Market Entry Justify Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on CRISPR Therapeutics stock - Investing.com
CRISPR Therapeutics (CRSP) Is Up 7.9% After Unveiling CTX460 Gene Editing Data for AAT Deficiency Therapy – Has The Bull Case Changed? - Sahm
CRISPR Therapeutics AG stock retracement – recovery analysisMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Measuring CRISPR Therapeutics AG’s beta against major indicesJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Can Owais Metal and Mineral Processing Limited Compete Against Disruptor Stocks in Its SectorStraddle and Strangle Trades & Free Stay Ahead With Picks - earlytimes.in
CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
4,245 Shares in CRISPR Therapeutics AG $CRSP Bought by Valeo Financial Advisors LLC - MarketBeat
Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data - TipRanks
CRISPR Therapeutics AG Hits New 52-Week High of $78.47 - Markets Mojo
CRISPR Therapeutics (CRSP): Valuation Perspective Following Breakthrough SyNTase Preclinical Data and Pipeline Progress - Sahm
CRSP: Needham Reiterates Buy Rating with $81 Target Price | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month HighShould You Buy? - MarketBeat
CRSP Showcases Promising Preclinical Data for AATD Treatment - GuruFocus
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform - The Manila Times
CRISPR Therapeutics Highlights Potential Best-in-Class AATD Treatment with CTX460 at ESGCT 2025 Annual Congress - Quiver Quantitative
>90% mRNA correction: CRISPR Therapeutics' CTX460 raises serum AAT >5-fold and shows durable in vivo editing - Stock Titan
Combining machine learning predictions for CRISPR Therapeutics AG2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
McElhenny Sheffield Capital Management LLC Invests $6.62 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
Multi factor analysis applied to CRISPR Therapeutics AG2025 Key Highlights & High Return Stock Watch Alerts - newser.com
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - ADVFN
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crispr Therapeutics Ag Azioni (CRSP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. | General Counsel and Secretary |
Oct 14 '25 |
Sale |
66.60 |
1,076 |
71,662 |
83,402 |
| Kulkarni Samarth | Chief Executive Officer |
Aug 18 '25 |
Sale |
58.15 |
13,081 |
760,660 |
207,004 |
| Treco Douglas A | Director |
Aug 06 '25 |
Buy |
57.03 |
20,000 |
1,140,600 |
22,000 |
| George Simeon | Director |
Jul 16 '25 |
Buy |
52.03 |
989,812 |
51,499,918 |
1,730,179 |
| Patel Naimish | Chief Medical Officer |
May 29 '25 |
Sale |
35.94 |
3,932 |
141,316 |
6,068 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):